// App-Quantinova.ai

903 : Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Researchers

Presenter

  • Silvia Franceschetti

Principal Investigators

  • Pier Luigi Zinzani

  • Flavia Salvi

  • Pier Paolo Fattori

  • Alfonso Zaccaria

  • Barbara Botto

  • Angela Congiu

  • Marco Ladetto

  • Martin Dreyling

  • Gianluca Gaidano

  • Giuseppe Rossi

  • Angelo Michele Carella

  • Umberto Vitolo

  • Ileana Baldi

  • Manuela Zanni

  • Anna Marina Liberati

  • Michele Spina

  • Chiara Bottelli

  • Vincenzo Pavone

  • Anna Lia Molinari

Medical Centers

  • University and CPO Piemonte, Unit of Cancer Epidemiology, Torino, Italy

  • Department of Internal Medicine III, Technical University of Munich, Munich, Germany

  • On the behalf of Fondazione Italiana Linfomi, Hematology , Citta della Salute e della Scienza Hospital and University, Torino, Italy,

  • Ematologia 1, A.O. Citt della Salute e della Scienza, Torino, Italy

Locations

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Deep vein thrombosis

  • Venous thrombosis

  • Thrombocytopenia

  • B cell lymphomas

  • Neutropenia

  • B-Cell Non-Hodgkin Lymphoma

  • Peripheral neuropathy

  • Lymphomas

  • Anemia

  • Sepsis

Biomarkers

  • B-lymphocyte antigen CD20

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Trimethoprim and sulfamethoxazole

  • Lenalidomide

  • Vincristine

  • Rituximab

  • Aspirin

  • Albyl-E

  • Heparin

  • Filgrastim

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT00907348

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved